Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Brachytherapy | Research

Ultrasound-guided implantation of radioactive ¹²⁵I seed in radioiodine refractory differentiated thyroid carcinoma

Authors: Wei Chen, Yu kun Luo, Ying Zhang, Qing Song, Jie Tang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Treatment for radioiodine refractory differentiated thyroid carcinoma (RR-DTC) is challenging. The purpose of this study was to assess the efficacy and safety of ultrasound-guided implantation of radioactive ¹²⁵I-seed in radioiodine refractory differentiated thyroid carcinoma.

Methods

Thirty-six cervical metastatic lymph nodes (CMLNs) diagnosed with RR-DTC from 18 patients were enrolled in this retrospective study. US and contrast-enhanced ultrasound (CEUS) examinations were performed before implantation. Follow-up comprised US, CEUS, thyroglobulin (Tg) level and routine hematology at 1–3, 6, 9 and 12 months and every 6 months thereafter. The volumes of the nodules were compared before implantation and at each follow-up point. The volume reduction rate (VRR) of nodules was also recorded.

Results

The median volume of the nodules was 523 mm³ (148, 2010mm³) initially, which decreased significantly to 53mm³ (0, 286mm³) (P < 0.01) at the follow-up point of 24 months with a median VRR as 95% (86,100%). During the follow-up period (the range was 24–50 months), 25 (69%) nodules had VRR greater than 90%, of which 12 (33%) nodules had VVR ≈ 100% with unclear structures and only ¹²⁵I seed images were visible in the US. At the last follow-up visit, the serum Tg level decreased from 57.0 (8.6, 114.8) ng/ml to 4.9 (0.7, 50.3) ng/ml, (P < 0.01).

Conclusion

US-guided ¹²⁵I seed implantation is safety and efficacy in treating RR- DTC. It could be an effective supplement for the comprehensive treatment of thyroid cancer.

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.CrossRef

Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2020. Cancer Res Treat. 2020;52(2):351–8. https://doi.org/10.4143/crt.2020.203.CrossRefPubMedPubMedCentral

Yan KL, Li S, Tseng CH, Kim J, Nguyen DT, Dawood NB, Livhits MJ, Yeh MW, Leung AM. Rising Incidence and Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017. J Clin Endocrinol Metab. 2020;105(6):1770-7.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentral

Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9. https://doi.org/10.1210/jc.2005-2838.CrossRefPubMed

Schlumberger M. Target therapies for radioiodine refractory advanced thyroid tumors. J Endocrinol Investig. 2012;35(6 Suppl):40–4.

Pacini F, Ito Y, Luster M, Pitoia F, Robinson B, Wirth L. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab. 2012;7(5):541–54. https://doi.org/10.1586/eem.12.36.CrossRefPubMed

Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98(1):31–40. https://doi.org/10.1002/cncr.11442.CrossRefPubMed

Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman JL. Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma. (REPRINTED) Arch Otolaryngol Head Neck Surg. 2004;130:819–24.CrossRef

10.

Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356–8. https://doi.org/10.1016/S2213-8587(13)70215-8.CrossRefPubMed

11.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30. https://doi.org/10.1056/NEJMoa1406470.CrossRefPubMed

12.

Gruber JJ, Colevas AD. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist. 2015;20(2):113–26. https://doi.org/10.1634/theoncologist.2014-0313.CrossRefPubMedPubMedCentral

13.

Triponez F, Poder L, Rasa Zarnegar RG, Roayaie K, Feldstein V, Lee J, et al. Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease. J Clin Endocrinol Metab. 2006;91(12):4943–7. https://doi.org/10.1210/jc.2006-0386.CrossRefPubMed

14.

Weiping Wang SML, R. Michael Tuttle, Hovanes Kalaigian, Katherine Kolbert, Martin Sonenberg, and Richard J. Robbins: Resistance of [18F]-Fluorodeoxyglucose–Avid Metastatic Thyroid Cancer Lesions to Treatment with High-Dose Radioactive Iodine. THYROID. 2004;11(12):1169-75.

15.

Huang H, Xu S, Li F, Du Z, Wang L. Clinical application of computed tomography-guided (125)I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases. Eur J Med Res. 2016;21(1):18. https://doi.org/10.1186/s40001-016-0213-1.CrossRefPubMedPubMedCentral

16.

Gao F, Li C, Gu Y, Huang J, Wu P. CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients. Eur J Radiol. 2013;82(2):e70–5. https://doi.org/10.1016/j.ejrad.2012.09.003.CrossRefPubMed

17.

Huang MW, Zheng L, Liu SM, Shi Y, Zhang J, Yu GY, et al. 125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region. Strahlenther Onkol. 2013;189(6):502–7. https://doi.org/10.1007/s00066-013-0324-3.CrossRefPubMed

18.

Lin L, Wang J, Jiang Y, Meng N, Tian S, Yang R, et al. Interstitial 125I seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma. Technol Cancer Res Treat. 2015;14(2):201–7. https://doi.org/10.7785/tcrt.2012.500409.CrossRefPubMed

19.

Zhu L, Jiang Y, Wang J, Ran W, Yuan H, Liu C, et al. An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy. World J Surg Oncol. 2013;11(1):60. https://doi.org/10.1186/1477-7819-11-60.CrossRefPubMedPubMedCentral

20.

Zhang L, Fan W-J, Huang J-h, Gu Y-k. CT guided ¹²⁵I seeds implantation in treatment of local recurrent rectal cancer after surgery resection: analysis of 21 cases. Chin Med J. 2008;88(19):1335–8.

21.

Gu IHM, Wu J-c, Jie C. Ultrasound-guided ¹²⁵I radioactive seed implantation in the treatment of recurrent or metastatic superficial malignant tumors. Chin J Med Imaging Technol. 2010;26(6):1155–7.

22.

Baek JH, Kim YS, Lee D, Huh JY, Lee JH. Benign predominantly solid thyroid nodules: prospective study of efficacy of sonographically guided radiofrequency ablation versus control condition. AJR Am J Roentgenol. 2010;194(4):1137–42. https://doi.org/10.2214/AJR.09.3372.CrossRefPubMed

23.

Hong YR, Luo ZY, Mo GQ, Wang P, Ye Q, Huang PT. Role of contrast-enhanced ultrasound in the pre-operative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma. Ultrasound Med Biol. 2017;43(11):2567–75. https://doi.org/10.1016/j.ultrasmedbio.2017.07.010.CrossRefPubMed

24.

Liu Y, Zhou H, Yang P, Zhou Y, Wu J, Chen C, et al. Contrast-enhanced ultrasonography features of papillary thyroid carcinoma for predicting cervical lymph node metastasis. Exp Ther Med. 2017;14(5):4321–7.PubMedPubMedCentral

25.

Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28. https://doi.org/10.1016/0002-9343(94)90321-2.CrossRefPubMed

26.

Rouxel A, Hejblum G, Bernier MO, Boëlle PY, Ménégaux F, Mansour G, et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2004;89(11):5362–8. https://doi.org/10.1210/jc.2003-032004.CrossRefPubMed

27.

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England). 2014;384(9940):319–28.CrossRef

28.

Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist. 2014;19(3):251–8. https://doi.org/10.1634/theoncologist.2013-0362.CrossRefPubMedPubMedCentral

29.

Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014;170(4):575–82. https://doi.org/10.1530/EJE-13-0825.CrossRefPubMed

30.

Kiess AP, Agrawal N, Brierley JD, Duvvuri U, Ferris RL, Genden E, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American head and neck society. Head Neck. 2016;38(4):493–8. https://doi.org/10.1002/hed.24357.CrossRefPubMed

31.

Pacella CM, Papini E. Image guided percutaneous ablation therapies for local recurrences of thyroid tumors. Endocrinol Invest. 2013;36:61–70.CrossRef

32.

Guang Y, Luo Y, Zhang Y, Zhang M, Li N, Zhang Y, et al. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. J Cancer Res Clin Oncol. 2017;143(8):1555–62. https://doi.org/10.1007/s00432-017-2386-6.CrossRefPubMed

33.

Teng D, Ding L, Wang Y, Liu C, Xia Y, Wang H. Safety and efficiency of ultrasound-guided low power microwave ablation in the treatment of cervical metastatic lymph node from papillary thyroid carcinoma: a mean of 32 months follow-up study. Endocrine. 2018;62(3):648–54. https://doi.org/10.1007/s12020-018-1711-4.CrossRefPubMed

34.

Kim SY, Kim SM, Chang H, Kim BW, Lim CY, Lee YS, et al. Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. Eur Arch Otorhinolaryngol. 2017;274(9):3497–501. https://doi.org/10.1007/s00405-017-4660-2.CrossRefPubMed

35.

Fontenot TE, Deniwar A, Bhatia P, Al-Qurayshi Z, Randolph GW, Kandil E. Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis. JAMA Otolaryngol Head Neck Surg. 2015;141(6):512–8. https://doi.org/10.1001/jamaoto.2015.0596.CrossRefPubMed

36.

Zhang L, Zhou W, Zhan W. Role of ultrasound in the assessment of percutaneous laser ablation of cervical metastatic lymph nodes from thyroid carcinoma. Acta Radiol. 2018;59(4):434–40. https://doi.org/10.1177/0284185117721261.CrossRefPubMed

37.

Mauri G, Cova L, Ierace T, Baroli A, Di Mauro E, Pacella CM, et al. Treatment of metastatic lymph nodes in the neck from papillary thyroid carcinoma with percutaneous laser ablation. Cardiovasc Intervent Radiol. 2016;39(7):1023–30. https://doi.org/10.1007/s00270-016-1313-6.CrossRefPubMed

38.

Lu W, Du P, Yang C, Jiang F, Xie P, Yang J, et al. The effect of computed tomography-guided (125)I radioactive particle implantation in treating cancer and its pain. Cancer Biother Radiopharm. 2018;33(5):176–81. https://doi.org/10.1089/cbr.2017.2425.CrossRefPubMed

39.

Tanderup K, Menard C, Polgar C, Lindegaard JC, Kirisits C, Potter R. Advancements in brachytherapy. Adv Drug Deliv Rev. 2017;109:15–25. https://doi.org/10.1016/j.addr.2016.09.002.CrossRefPubMed

40.

Deng X, Wu H, Gao F, Su Y, Li Q, Liu S, et al. Brachytherapy in the treatment of breast cancer. Int J Clin Oncol. 2017;22(4):641–50. https://doi.org/10.1007/s10147-017-1155-5.CrossRefPubMed

41.

Chen P, Wu WJ, Yi ZQ, Ma XL, Zhao WH, Zhang JG. (125) I interstitial brachytherapy in management of pediatric skull base tumors. Pediatr Blood Cancer. 2019;66(5):e27622. https://doi.org/10.1002/pbc.27622.CrossRefPubMed

42.

Xing M. BRAF mutation and thyroid cancer recurrence. J Clin Oncol. 2015;33(22):2482–3. https://doi.org/10.1200/JCO.2015.61.4016.CrossRefPubMed

43.

Bible KC, Ryder M. Mutated BRAF and personalised medicine in differentiated thyroid cancer. Lancet Oncol. 2016;17(9):1181–3. https://doi.org/10.1016/S1470-2045(16)30230-3.CrossRefPubMed

44.

Meng J, Wang X, Zhuang QW, Gu QP, Zhang J, Li ZP. Clinical effectiveness of 125I-seed implantation in combination with nimotuzumab therapy for the advanced oral carcinoma: preliminary results. Eur Rev Med Pharmacol Sci. 2014;18(21):3304–10.PubMed

Title: Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Authors: Wei Chen
Yu kun Luo
Ying Zhang
Qing Song
Jie Tang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Brachytherapy
Ultrasound
Metastasis
Ultrasound
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08500-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling

Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma

The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

The 5-year overall survival of cervical cancer in stage IIIC-r was little different to stage I and II: a retrospective analysis from a single center

Correction to: Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy

High regional mortality due to malignant melanoma in Eastern Finland may be explained by the increase in aggressive melanoma types

Keynote webinar | Spotlight on antibody–drug conjugates in cancer